Looking at the effect of the drug itself, we have seen direct impacts on the patients themselves
A significant side effect of the drug was that of better weight loss and weight management
Despite significant ablation advancements, AFibs recurrence risk is ~30% at one year and rises over time, likely due to cardiometabolic factors like obesity
You may have three competitors in the U.S., but you may have triple that in China
Our Senior Director of Pharmacy Strategy and Policy, Nicole Dawley, provides valuable insights into the background of the obesity epidemic, the science behind these medications and the importance of integrating them into a comprehensive weight management program
But it also creates new forms of risk concerning needle safety, unsettling patient-practitioner relationships via unregulated use, and the subversion of public health messages that groups such as Cancer Council Australia have worked for decades to promote.